Companies /Healthcare

AdaptHealth Corp

NASDAQ: AHCO Medical Devices
$5.80
â–² $0.13 (+2.29%) today
Markets closed · 10:56pm ET

Q3 2025 Earnings

Reported Nov 4, 2025, 7:06am ET · SEC source
$0.16
Miss −33.14%
EPS · est. $0.24
$820.3M
Beat +2.63%
Revenue · est. $799.3M
−13.3%
Trailing market
AHCO vs S&P since report
6 quarters
Consecutive EPS misses

Market Reaction

% change · around the report
0+5%+10%+15%Nov 4Nov 5report 7:06am ETearnings+0.7%+9.8%
0+5%+10%+15%Nov 4Nov 5earnings+0.7%+9.8%
AHCO +9.8%S&P 500 +0.7%
0+6%+12%Nov 4Nov 5report 7:06am ETearnings+0.3%+9.8%
0+6%+12%Nov 4Nov 5earnings+0.3%+9.8%
AHCO +9.8%NASDAQ +0.3%
−6%0+6%+12%Nov 3Nov 11report 7:06am ETearnings+1.0%+1.1%
−6%0+6%+12%Nov 3Nov 11earnings+1.0%+1.1%
AHCO +1.1%S&P 500 +1.0%
−6%0+6%+12%Nov 3Nov 11report 7:06am ETearnings−0.2%+1.1%
−6%0+6%+12%Nov 3Nov 11earnings−0.2%+1.1%
AHCO +1.1%NASDAQ −0.2%
+17.38%
Day of report
−3.09%
Next session
−10.59%
One week
−11.72%
30 days

S&P 500 over the same 30 days: +1.55%.

Did AHCO Beat Earnings? Q3 2025 Results

AdaptHealth delivered a mixed but broadly encouraging Q3 2025, beating revenue expectations while falling short on earnings in a quarter CEO Suzanne Foster called a "milestone." The home medical equipment provider posted revenue of $820.31 million, up 37.3% year-over-year and ahead of the $799.31 million consensus, but GAAP EPS of $0.16 missed the $0.24 analyst estimate by 33.14%, weighed down by higher cost of net revenue and elevated capital expenditures of $94.24 million as the company invests in equipment and infrastructure. The most material driver of revenue momentum was organic growth of 5.1%, the strongest since Q1 2024, reflecting solid volume trends across all four business segments. On the balance sheet, AdaptHealth repaid $50 million in debt during the quarter, bringing year-to-date repayments to $225 million and a net leverage ratio of 2.68x, drawing a credit rating upgrade on its senior unsecured debt. The company also secured a new capitated agreement covering roughly 170,000 members, signaling continued expansion in value-based care. Full-year 2025 guidance was maintained, with net revenue targeted at $3.18 billion to $3.26 billion and Adjusted EBITDA of $642 million to $682 million.

Key Takeaways
  • Organic revenue growth of 5.1%, highest since Q1 2024, driven by solid underlying volume trends across all four reportable segments
  • Adjusted EBITDA margin expanded to 20.7% from 20.4% year-over-year
  • Interest expense reduced to $25.4 million from $31.4 million due to debt reduction
  • myApp registered users grew to 271,000 from 118,000 in Q3 2024

“Q3 was a milestone quarter for AdaptHealth. We delivered strong financial results that exceeded our expectations, made substantial operational improvements across the organization, and continued building foundational capabilities to drive sustainable growth. The quarter demonstrated both the progress we've made and the significant opportunity ahead.”

AdaptHealth CEO, on the earnings call

Forward Guidance & Outlook

AdaptHealth is maintaining its fiscal year 2025 financial guidance: net revenue of $3.18 billion to $3.26 billion, Adjusted EBITDA of $642 million to $682 million, and free cash flow of $170 million to $190 million. The guidance excludes the impact of any potential additional future strategic acquisitions and any items not yet identified and quantified.

AHCO YoY Financials

Q3 2025 vs Q3 2024 · SEC filings Q3 2024 Q3 2025
$0$300.0M$600.0M$900.0M$597.5M$820.3MRevenue$63.5M$61.7MOperating Income$22.9M$25.8MNet Income
$0$300.0M$600.0M$900.0MRevenueOperating IncomeNet Income

Figures from SEC filings and company reports. Not investment advice.